Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
06/30/2025
12/31/2024
06/30/2024
12/31/2023
Revenue
61,516
30,572
30,944
30,647
29,848
28,937
Revenue Growth (YoY)
2%
0%
4%
6%
0%
-7%
Cost of Revenue
16,230
8,481
7,749
8,311
7,472
7,982
Gross Profit
45,286
22,091
23,195
22,336
22,376
20,955
Selling, General & Admin
13,838
7,330
6,508
7,382
6,376
7,013
Research & Development
12,243
6,169
6,074
6,774
6,268
6,788
Operating Expenses
24,118
12,585
11,533
13,187
11,438
12,979
Other Non Operating Income (Expenses)
-159
-78
-81
-84
-88
-99
Pretax Income
16,973
7,385
9,588
3,570
8,223
4,905
Income Tax Expense
3,174
1,418
1,756
1,080
1,526
110
Net Income
12,880
5,470
7,410
2,019
6,258
4,361
Net Income Growth
56%
171%
18%
-54%
-12%
12%
Shares Outstanding (Diluted)
803
803
803
802
802
804
Shares Change (YoY)
0%
0%
0%
0%
0%
0%
EPS (Diluted)
16.03
6.81
9.22
2.52
7.8
5.42
EPS Growth
55%
170%
18%
-54%
-12%
12%
Free Cash Flow
10,906
6,967
3,939
9,263
5,822
5,522
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
73.61%
72.25%
74.95%
72.88%
74.96%
72.41%
Operating Margin
34.41%
31.09%
37.68%
29.85%
36.64%
27.56%
Profit Margin
20.93%
17.89%
23.94%
6.58%
20.96%
15.07%
Free Cash Flow Margin
17.72%
22.78%
12.72%
30.22%
19.5%
19.08%
EBITDA
21,471
9,648
11,823
9,317
11,121
8,142
EBITDA Margin
34.9%
31.55%
38.2%
30.4%
37.25%
28.13%
D&A For EBITDA
303
142
161
168
183
166
EBIT
21,168
9,506
11,662
9,149
10,938
7,976
EBIT Margin
34.41%
31.09%
37.68%
29.85%
36.64%
27.56%
Effective Tax Rate
18.7%
19.2%
18.31%
30.25%
18.55%
2.24%
Follow-Up Questions
Báo cáo tài chính chính của Roche Holding AG là gì?
Theo báo cáo tài chính mới nhất (Form-10K), Roche Holding AG có tổng tài sản là $0, lợi nhuận ròng loss là $0
Tỷ lệ tài chính chính của RHHBY là gì?
Tỷ lệ thanh khoản của Roche Holding AG là 0, tỷ suất lợi nhuận ròng là 0, doanh thu trên mỗi cổ phiếu là $0.
Doanh thu của Roche Holding AG được phân bổ theo phân khúc hoặc khu vực địa lý như thế nào?
Roche Holding AG largest revenue segment is Oil, at a revenue of 1,100,483,000 in the most earnings release.For geography, Ghana is the primary market for Roche Holding AG, at a revenue of 631,722,000.
Roche Holding AG có lợi nhuận không?
no, theo báo cáo tài chính mới nhất, Roche Holding AG có lợi nhuận ròng loss là $0
Roche Holding AG có nợ không?
no, Roche Holding AG có nợ là 0
Roche Holding AG có bao nhiêu cổ phiếu đang lưu hành?
Roche Holding AG có tổng cộng 0 cổ phiếu đang lưu hành